105,273 Shares in Savara Inc. $SVRA Bought by Glenmede Trust Co. NA

Glenmede Trust Co. NA purchased a new stake in Savara Inc. (NASDAQ:SVRA) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 105,273 shares of the company’s stock, valued at approximately $575,000. Glenmede Trust Co. NA owned about 0.05% of Savara as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Osaic Holdings Inc. lifted its holdings in shares of Savara by 6.9% during the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock worth $197,000 after acquiring an additional 2,098 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Savara by 3.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock valued at $420,000 after acquiring an additional 2,116 shares during the period. Graham Capital Management L.P. increased its stake in Savara by 4.9% in the fourth quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock valued at $338,000 after acquiring an additional 2,615 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Savara by 9.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock worth $200,000 after purchasing an additional 2,859 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Savara by 48.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after purchasing an additional 3,205 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on SVRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Oppenheimer began coverage on Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Savara currently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Stock Performance

NASDAQ SVRA opened at $5.83 on Friday. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -10.41 and a beta of 0.29. The company has a 50 day moving average of $5.62 and a 200-day moving average of $5.50. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. Savara Inc. has a 1-year low of $2.43 and a 1-year high of $7.01.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, equities analysts forecast that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.